Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Classificação em ações #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Preço da ação
$207.15
Valor de mercado
$366.28B
Variação (1 dia)
0.99%
Variação (1 ano)
2.91%
País
US
Negociar AbbVie Inc. (ABBV)

Categoria

Histórico de preços das ações de AbbVie Inc. (ABBV)
Preço de fecho mais alto: $220.67 em 2026-03-01

Preço de fecho mais baixo: $35.68 em 2013-01-01
Histórico de preços das ações da AbbVie Inc. de 2013 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -7.43%
2025 28.51%
2024 16.39%
2023 -7.17%
2022 27.60%
2021 21.67%
2020 19.07%
2019 0.53%
2018 -9.28%
2017 57.12%
2016 7.67%
2015 -15.03%
2014 29.37%
2013 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$916.42 10.84%
US
$187.14 157.34%
GB
$239.93 48.36%
US
$150.75 36.87%
CH
$119.37 35.48%
US